Literature DB >> 9843741

Hepatic glucose uptake rapidly decreases after removal of the portal signal in conscious dogs.

P S Hsieh1, M C Moore, D W Neal, A D Cherrington.   

Abstract

The aim of this study was to assess the decay of the effect of the portal signal on net hepatic glucose uptake (NHGU). Experiments were performed on five 42-h-fasted conscious dogs. After the 40-min basal period, somatostatin was given peripherally along with insulin (1.8 pmol. kg-1. min-1) and glucagon (0.65 ng. kg-1. min-1) intraportally. In the first experimental period (Pe-GLU-1; 90 min), glucose was infused into a peripheral vein to double the glucose load to the liver (HGL). In the second experimental period (Po-GLU; 90 min), glucose (20.1 micromol. kg-1. min-1) was infused intraportally and the peripheral glucose infusion was reduced to maintain the same HGL. In the third period (Pe-GLU-2; 120 min), the portal glucose infusion was stopped and the peripheral glucose infusion was increased to again sustain HGL. Arterial insulin levels (42 +/- 3, 47 +/- 3, 43 +/- 3 pmol/l) were basal and similar in the Pe-GLU-1, Po-GLU, and Pe-GLU-2 periods, respectively. Arterial glucagon levels were also basal and similar (51 +/- 3, 49 +/- 2, 46 +/- 2 ng/l) in the three experimental periods. The glucose loads to the liver were 251 +/- 11, 274 +/- 14, and 276 +/- 12 micromol. kg-1. min-1, respectively. NHGU was 6.3 +/- 2.4, 19.1 +/- 2.8, and 9.2 +/- 1.2 micromol. kg-1. min-1, and nonhepatic glucose uptake (non-HGU) was 23.6 +/- 3.0, 5.3 +/- 1.8, and 25.5 +/- 3.7 micromol. kg-1. min-1 in the three periods, respectively. Cessation of the portal signal for only 10 min shifted NHGU and non-HGU to 9.4 +/- 2.2 and 25.0 +/- 2.8 micromol. kg-1. min-1, respectively; thus the effect of the portal signal was rapidly reversed both at the liver and peripheral tissues.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843741     DOI: 10.1152/ajpendo.1998.275.6.E987

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Hepatic glycogen can regulate hypoglycemic counterregulation via a liver-brain axis.

Authors:  Jason J Winnick; Guillaume Kraft; Justin M Gregory; Dale S Edgerton; Phillip Williams; Ian A Hajizadeh; Maahum Z Kamal; Marta Smith; Ben Farmer; Melanie Scott; Doss Neal; E Patrick Donahue; Eric Allen; Alan D Cherrington
Journal:  J Clin Invest       Date:  2016-05-03       Impact factor: 14.808

2.  A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo.

Authors:  Zhibo An; Jason J Winnick; Ben Farmer; Doss Neal; Margaret Lautz; Jose M Irimia; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2010-09-07       Impact factor: 9.461

3.  Portal infusion of escitalopram enhances hepatic glucose disposal in conscious dogs.

Authors:  Zhibo An; Mary C Moore; Jason J Winnick; Ben Farmer; Doss W Neal; Margaret Lautz; Marta Smith; Tiffany Rodewald; Alan D Cherrington
Journal:  Eur J Pharmacol       Date:  2009-04-01       Impact factor: 4.432

4.  Liver glycogen-induced enhancements in hypoglycemic counterregulation require neuroglucopenia.

Authors:  Shana O Warner; Abby M Wadian; Marta Smith; Ben Farmer; Yufei Dai; Nicole Sheanon; Dale S Edgerton; Jason J Winnick
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-03-29       Impact factor: 4.310

5.  A cyclic guanosine monophosphate-dependent pathway can regulate net hepatic glucose uptake in vivo.

Authors:  Zhibo An; Jason J Winnick; Mary C Moore; Ben Farmer; Marta Smith; Jose M Irimia; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.461

6.  Hepatic glycogen supercompensation activates AMP-activated protein kinase, impairs insulin signaling, and reduces glycogen deposition in the liver.

Authors:  Jason J Winnick; Zhibo An; Christopher J Ramnanan; Marta Smith; Jose M Irimia; Doss W Neal; Mary Courtney Moore; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

7.  C-peptide enhances glucagon secretion in response to hyperinsulinemia under euglycemic and hypoglycemic conditions.

Authors:  Mary Courtney Moore; Shana O Warner; Yufei Dai; Nicole Sheanon; Marta Smith; Ben Farmer; Rebecca L Cason; Alan D Cherrington; Jason J Winnick
Journal:  JCI Insight       Date:  2021-06-22

8.  Liver glycogen loading dampens glycogen synthesis seen in response to either hyperinsulinemia or intraportal glucose infusion.

Authors:  Jason J Winnick; Zhibo An; Guillaume Kraft; Christopher J Ramnanan; Jose M Irimia; Marta Smith; Margaret Lautz; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2012-08-24       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.